Advertisement

Interferon gamma zur Behandlung der Rheumatoiden Arthritis. Ergebnisse von Therapiestudien bei 850 Patienten

  • H. J. Obert
  • J. F. Brzoska
  • M. P. Hündgen
Conference paper

Summary

Interferon gamma (IFN-7) is a new agent for treating rheumatoid arthritis (RA). Since 1983 we have performed several clinical trials of phase I-IV. Under a systemic treatment (s.c.) with stepwise reduction of the dosage RA is improved in 60% of the patients. Pain, morning stiffness and function of the joints are markedly changed followed by improvement of parameters such as erythrocyte sedimentation rate, anemia, thrombocytosis, or leukocytosis. Concomitant medication with corticosteroids can be reduced. The effectiveness could be shown in a placebo controlled, double blind randomized clinical trial. IFN-γ is tolerated well. Main side effects are flue like symptoms.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Brzoska J, Obert HJ (1987) Interferon gamma: ein janusköpfiger Mediator bei Entzündungen. Arzneim-Forsch/Drug Res 37:1410–1416Google Scholar
  2. 2.
    Dinarello CA (1985) An update of human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol 5:287–297PubMedCrossRefGoogle Scholar
  3. 3.
    Hartl PW (1984) Erkrankungen des rheumatischen Formenkreises. In: Siegenthaler W, Kaufmann W, Hornbostel H, Walter HD (eds) Lehrbuch der inneren Medizin. Thieme, Stuttgart New York, pp 8.1–8.31Google Scholar
  4. 4.
    Klein HO (1988) Therapie der rheumatoiden Arthritis mit rekombinantem Interferon-gamma. Fortschr Med 106(36):721–725PubMedGoogle Scholar
  5. 5.
    Lemmel EM, Brackertz D, Franke M, Gaus W, Hartl PW, Machalke K, Mielke H, Obert HJ, Peter HH, Sieper J, Sprekeler R, Stierle H (1988) Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int 8:87–93PubMedCrossRefGoogle Scholar
  6. 6.
    Lemmel EM, Franke M, Gaus W, Hartl PW, Hofschneider PH, Miehlke K, Machalke K, Obert HJ (1987) Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int 7:127–132PubMedCrossRefGoogle Scholar
  7. 7.
    Obert HJ, Brzoska J (1986) Interferon-gamma in der Therapie der chronischen Polyarthritis. Arzneim-Forsch/Drug Res 36:1557–1560Google Scholar
  8. 8.
    Obert HJ, Brzoska JF (1989) Interferon gamma in der Therapie der chronischen Polyarthritis. Die Langzeitbehandlung in der Praxis. Arznei Forsch/Drug Res 39:819–822Google Scholar
  9. 9.
    Obert HJ, Hofschneider PH (1985) Interferon bei chronischer Polyarthritis. Dtsch Med Wschr 110:1766–1769PubMedCrossRefGoogle Scholar
  10. 10.
    Rowe FM, Edwards J, Cozens PJ (1987) Increased interleukin-1 levels from monocytes of rheumatoid arthritis patients during the early stages of the disease are down regulated in vitro by the addition of interferon gamma. J Leuk Biol 42:600–601Google Scholar
  11. 11.
    Seitz M, Napierski I, Augustin R, Hunstein W, Kirchner H (1987) Reduced production of interferon alpha and interferon gamma in leukocyte cultures from patients with active rheumatoid arthritis. Scand J Rheumatol 16:257–262PubMedCrossRefGoogle Scholar
  12. 12.
    Sprekeler R (1988) Die Behandlung der rheumatoiden Arthritis (RA) mit rekombinantem Gamma-Interferon. In: Heidemann E (ed) Klinische Erfahrungen mit Interferon beta und gamma. Akt Immunol vol 4. Zuckschwerdt, München Bern Wien San Francisco, pp 35–41Google Scholar
  13. 13.
    Stolzenburg T, Binz H, Fontana A, Felder M, Wagenhäuser FJ (1988) Impaired mitogen-induced interferon gamma production in rheumatoid arthritis and related diseases. Scand J Immunol 27:73–81PubMedCrossRefGoogle Scholar
  14. 14.
    Veys EM, Mielans H, Verbruggen G, Grosclaude JP, Meyer W, Galazka A, Schindler J (1988) Interferon gamma in rheumatoid arthritis — a double blind study comparing human recombinant interferon gamma with placebo. J Rheumatol 15:570–574PubMedGoogle Scholar
  15. 15.
    Wolfe F, Cathey MA, Hawley DJ, Baiser JP, Schindler JD (1986) Clinical trial with rIFN-gamma in rheumatoid arthritis. In: Pincus SH, Pisetsky DS, Rosenwasser LJ (eds) Biologically based immunomodulators in the therapy of rheumatic diseases, Elsevier, New York Amsterdam London pp 379–395Google Scholar

Copyright information

© Springer-Verlag · Heidelberg 1989

Authors and Affiliations

  • H. J. Obert
    • 1
  • J. F. Brzoska
    • 1
  • M. P. Hündgen
    • 2
  1. 1.Bioferon, Biochemische Substanzen GmbH & Co.LaupheimGermany
  2. 2.Dr. Rentschier, Arzneimittel GmbH & Co.LaupheimGermany

Personalised recommendations